Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
DMK Pharmaceuticals Corp (DMK), formerly Adamis Pharmaceuticals Corporation, is a commercial-stage neuro-biotech company that develops and commercializes products for the treatment of opioid overdose and substance use disorders. The company’s pipeline includes SYMJEPI, ZIMHI, DPI-125, DPI-221 and DPI-289. Its pipeline candidates treat anaphylaxis, opioid overdose, opioid use disorder, benign prostatic hyperplasia and parkinson’s disease. DMK develops products in the form of injections, gels and capsules for the treatment of allergies, opioid overdose and respiratory and inflammatory disease. The company supplies its products to doctors, ambulatory surgery centers, healthcare systems, hospitals and veterinarians across the US. DMK is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
11682 El Camino Real, Suite 300, San Diego, California, 92130
Website
www.dmkpharmaceuticals.com
Telephone
1 858 9972400
No of Employees
11
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DMKPQ (OTC)
Revenue (2021)
$4.8M
115.3%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
42.2%
(2021 vs 2020)
Market Cap*
$340,000
Net Profit Margin (2021)
XYZ
73.2%
(2021 vs 2020)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| SYMJEPI: Anaphylaxis | SYMJEPI |
| ZIMHI: Opioid Overdose | ZIMHI |
| DPI-125: Opioid Use Disorder | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In December, the company acquired the full rights to commercialize ZIMHI. |
| 2023 | Plans/Strategy | In November, the company announced plans to acquire the rights to its SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products from USWM, LLC. |
| 2023 | Corporate Changes/Expansions | In September, the company changed its name from Adamis Pharmaceuticals Corporation to DMK Pharmaceuticals Corporation. |
Competitor Comparison
| Key Parameters | DMK Pharmaceuticals Corp | Fortress Biotech Inc | Abeona Therapeutics Inc | Amryt Pharma Plc | Edesa Biotech Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | Canada |
| City | San Diego | Bay Harbor Islands | Cleveland | London | Markham |
| State/Province | California | Florida | Ohio | - | Ontario |
| No. of Employees | 11 | 186 | 84 | - | 16 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dr. Eboo Versi, MD PhD | Chief Executive Officer; Director | Executive Board | - | - |
| Seth Cohen | Chief Financial Officer | Senior Management | 2023 | - |
| John Dorbin | Corporate Secretary; General Counsel | Senior Management | 2023 | - |
| Howard C. Birndorf | Director | Non Executive Board | - | - |
| Meera J. Desai, PhD | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer